King Luther Capital Management Corp Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL)

King Luther Capital Management Corp reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,907 shares of the medical research company’s stock after selling 10,656 shares during the quarter. King Luther Capital Management Corp owned 0.79% of Charles River Laboratories International worth $84,501,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. ProShare Advisors LLC increased its holdings in Charles River Laboratories International by 15.6% in the 2nd quarter. ProShare Advisors LLC now owns 12,840 shares of the medical research company’s stock valued at $2,700,000 after purchasing an additional 1,731 shares in the last quarter. WESCAP Management Group Inc. increased its holdings in Charles River Laboratories International by 5.9% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,739 shares of the medical research company’s stock valued at $576,000 after purchasing an additional 153 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Charles River Laboratories International by 19.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 28,077 shares of the medical research company’s stock valued at $5,903,000 after purchasing an additional 4,629 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Charles River Laboratories International by 2.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,089 shares of the medical research company’s stock valued at $4,005,000 after purchasing an additional 479 shares in the last quarter. Finally, J.P. Marvel Investment Advisors LLC increased its holdings in Charles River Laboratories International by 6.5% in the 2nd quarter. J.P. Marvel Investment Advisors LLC now owns 38,802 shares of the medical research company’s stock valued at $8,158,000 after purchasing an additional 2,380 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of several recent research reports. StockNews.com initiated coverage on Charles River Laboratories International in a report on Thursday, October 5th. They issued a “hold” rating for the company. Bank of America lowered their price target on Charles River Laboratories International from $245.00 to $230.00 in a report on Friday, September 22nd. UBS Group lowered their target price on Charles River Laboratories International from $250.00 to $215.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. Robert W. Baird lowered their target price on Charles River Laboratories International from $267.00 to $256.00 and set an “outperform” rating for the company in a research note on Friday, September 22nd. Finally, Evercore ISI lowered their target price on Charles River Laboratories International from $235.00 to $225.00 in a research note on Wednesday, October 11th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $232.54.

Charles River Laboratories International Stock Up 0.0 %

NYSE:CRL traded up $0.01 during mid-day trading on Monday, reaching $189.05. The stock had a trading volume of 13,017 shares, compared to its average volume of 527,670. The company has a market capitalization of $9.69 billion, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 2.00 and a beta of 1.35. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $262.00. The stock’s 50 day simple moving average is $188.54 and its two-hundred day simple moving average is $198.28. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.45 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported $2.72 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.37. Charles River Laboratories International had a return on equity of 18.15% and a net margin of 11.27%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm earned $2.63 earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.58 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, CEO James C. Foster bought 5,620 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average price of $178.05 per share, with a total value of $1,000,641.00. Following the completion of the acquisition, the chief executive officer now directly owns 202,643 shares of the company’s stock, valued at approximately $36,080,586.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Charles River Laboratories International news, CEO James C. Foster bought 5,620 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average price of $178.05 per share, with a total value of $1,000,641.00. Following the completion of the acquisition, the chief executive officer now directly owns 202,643 shares of the company’s stock, valued at approximately $36,080,586.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard F. Wallman bought 1,000 shares of the business’s stock in a transaction on Thursday, August 24th. The stock was acquired at an average cost of $198.79 per share, for a total transaction of $198,790.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $198,790. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).